Home » Stocks » ABIO

ARCA biopharma, Inc. (ABIO)

Stock Price: $3.50 USD 0.06 (1.74%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
After-hours: $3.51 +0.01 (0.29%) Apr 22, 7:50 PM
Market Cap 49.57M
Revenue (ttm) n/a
Net Income (ttm) -9.74M
Shares Out 4.71M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $3.50
Previous Close $3.44
Change ($) 0.06
Change (%) 1.74%
Day's Open 3.44
Day's Range 3.42 - 3.57
Day's Volume 229,803
52-Week Range 3.20 - 22.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WESTMINSTER, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

1 month ago - GlobeNewsWire

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other stocks mentioned: ATHA, MTCR
2 months ago - GuruFocus

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00...

4 months ago - GlobeNewsWire

Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 t...

4 months ago - Market Watch

WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

4 months ago - GlobeNewsWire

WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

5 months ago - GlobeNewsWire

WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

6 months ago - GlobeNewsWire

WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

6 months ago - GlobeNewsWire

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap...

7 months ago - GlobeNewsWire

WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapi...

8 months ago - GlobeNewsWire

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically target...

10 months ago - GlobeNewsWire

WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically target...

10 months ago - GlobeNewsWire

Shares of Arca Biopharma tripled in value Thursday after the biotech company announced it would develop a coronavirus treatment for patients with abnormal blood clotting. The post Arca Biopharma Stock T...

10 months ago - Investors Business Daily

Arca Biopharma Inc (NASDAQ: ABIO) shares are skyrocketing toward their highest level in more than a year following an announcement from the company regarding its plan to develop a COVID-19 treatment.

10 months ago - Benzinga

WESTMINSTER, Colo., May 28, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue f...

10 months ago - GlobeNewsWire

New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence

11 months ago - GlobeNewsWire

WESTMINSTER, Colo., May 06, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

11 months ago - GlobeNewsWire

WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therap...

1 year ago - GlobeNewsWire

ARCA biopharma published positive results from its phase 2b GENETIC-AF study using Gencaro to treat patients with genetically-defined heart failure with atrial fibrillation.

1 year ago - Seeking Alpha

Pharma CEO defends 400% price hike as moral requirement

YouTube video

The "Squawk Box" news team discusses some of the morning's most provocative headlines.

Other stocks mentioned: JWN
2 years ago - CNBC Television

About ABIO

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial ... [Read more...]

Industry
Biotechnology
CEO
Michael Bristow
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
ABIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ARCA biopharma is 7.00, which is an increase of 100.00% from the latest price.

Price Target
$7.00
(100.00% upside)